it How a custom plastic injection moulder is coping with the rise in demand due to Covid-19 By www.medicalplasticsnews.com Published On :: Mon, 27 Apr 2020 11:00:09 -0000 Diversified Plastics (DPI), a custom plastic injection moulder and additive manufacturer of high-precision components, has increased the capacity of its Acceleration Station to meet the rise in demand associated with the Covid-19 pandemic. Full Article
it How manufacturers can ensure quality of plastic components By www.medicalplasticsnews.com Published On :: Mon, 27 Apr 2020 12:18:04 -0000 Stephen Sanderson, group inspection product manager and Guven Turemen, group metrology product manager, both from manufacturer Vision Engineering, discusses how manufacturers can ensure the quality of plastic components. Full Article
it AdvaMed asks for additional tariff relief to tackle Covid-19 By www.medicalplasticsnews.com Published On :: Thu, 30 Apr 2020 09:35:03 -0000 The Advanced Medical Association (AdvaMed) has requested the United States Trade Representative (USTR) provides additional tariff exclusions for medical devices, components and supplies coming from China which are necessary to help with Covid-19. Full Article
it Sumitomo (SHI) Demag announces joint venture to strengthen market presence By www.medicalplasticsnews.com Published On :: Thu, 30 Apr 2020 09:56:39 -0000 The new company called PlastiKCs, was founded by injection moulding expert Kurt Callewaert, together with Thiele & Kor Plastics Machinery, a long-standing representative of Sumitomo (SHI) Demag. Full Article
it Röchling supplies thermoplastic components to help with the pandemic By www.medicalplasticsnews.com Published On :: Thu, 30 Apr 2020 10:26:13 -0000 Röchling Engineering Plastics UK is supporting the medical and healthcare sectors with thermoplastic components and materials to assist the NHS and worldwide OEMs. Full Article
it This week's top 5: Editor's pick By www.medicalplasticsnews.com Published On :: Fri, 01 May 2020 09:00:00 -0000 Our editor Laura Hughes highlights her five must-read articles for this week. Full Article
it Adhesives specialist launches campaign to improve productivity By www.medicalplasticsnews.com Published On :: Mon, 04 May 2020 11:09:59 -0000 Adhesives specialist Intertronics has launched a new campaign to highlight the ways that assembly companies can simplify processes, improve output and reduce waste. Full Article
it How a chemicals company is helping with the Covid-19 pandemic By www.medicalplasticsnews.com Published On :: Mon, 04 May 2020 11:38:33 -0000 Chemicals company Lubrizol is helping with the pandemic by making materials used in Personal Protection Equipment (PPE) as well as hand sanitiser and products to help treat patients who are fighting the virus. Full Article
it University of Glasgow issues plea for acetate sheets to help produce plastic visors By www.medicalplasticsnews.com Published On :: Mon, 04 May 2020 14:02:24 -0000 Engineers from the University of Glasgow are responding to the coronavirus pandemic by producing up to 1,000 pieces of Personal Protective Equipment (PPE) each day. Full Article
it Mitsubishi Chemical America acquires Gelest By www.medicalplasticsnews.com Published On :: Mon, 04 May 2020 15:28:35 -0000 Mitsubishi Chemical America has entered into a definitive agreement to acquire all of the issued and outstanding shares of Gelest Intermediate Holdings, the parent of Gelest, and a portfolio company of New Mountain Capital. Full Article
it How labelling could help with HAIs during the pandemic By www.medicalplasticsnews.com Published On :: Tue, 05 May 2020 11:51:26 -0000 Polyfuze Graphics, a global manufacturer of polymer fusion technology products for safety labelling and graphics, has introduced an antimicrobial safety product to help with Healthcare Associated Infections (HAIs) during the Covid-19 pandemic. Full Article
it Manufacturer forms alliance to cope with the demand for PPE By www.medicalplasticsnews.com Published On :: Tue, 05 May 2020 15:48:04 -0000 Manufacturer and designer, Placon, has introduced the Face Shield Alliance to provide healthcare workers and first responders with adequate Personal Protective Equipment (PPE) during the Covid-19 pandemic. Full Article
it Manufacturer vows to work ‘round-the-clock' to provide healthcare workers with PPE By www.medicalplasticsnews.com Published On :: Wed, 06 May 2020 13:54:58 -0000 To help with the increased demand for Personal Protective Equipment (PPE), Suffolk based manufacturer Broadwater Mouldings have turned over its 3D printer to produce protective shield frames for healthcare workers. Full Article
it This week's top 5: Editor's pick By www.medicalplasticsnews.com Published On :: Thu, 07 May 2020 09:00:00 -0000 Our editor Laura Hughes highlights her five must-read articles for this week. Full Article
it Morning Break: Black Licorice Warning; Obamacare Questions; Haunted Hospitals By www.medpagetoday.com Published On :: Tue, 31 Oct 2017 09:00:00 -0400 Health news and commentary from around the Web gathered by the ALLMedPage Today staff Full Article
it Huffington Post: Data Exclusivity: Getting the Balance Right By patentlybiotech.wordpress.com Published On :: Tue, 24 May 2011 19:12:55 +0000 Huffington Post: Data Exclusivity: Getting the Balance Right A great article on the downsides of cutting or removing data exclusivity provisions for biologics. The article points out that data protection is needed to enhance safety and create incentives to research and produce new innovative drugs that cost billions of dollars. However, the author argues that the period must be […] Full Article Uncategorized 12 years exclusivity Biologics data exclusivity huffington post incentivizing drug development
it University-Industry Partnering at BIO Convention Webinar by AUTM June 16, 3-4PM By patentlybiotech.wordpress.com Published On :: Wed, 15 Jun 2011 21:47:40 +0000 Get the inside information on what industry does and does NOT want from their academic counterparts: Join us June 16, 3-4 p.m. EDT for Insider’s Guide to Effective Partnering at BIO 2011, a FREE AUTM webinar to help you prepare for the BIO convention in Washington, DC, June 27-30. Full Article Uncategorized AUTM BIO partnering
it Crescendo links with CRUK to progress cancer therapy By www.pharmatimes.com Published On :: Tue, 05 May 2020 10:23:22 +0100 The charity's Centre for Drug Development will sponsor and fund a future Phase I clinical trial for CB213 Full Article
it Sanofi/Regeneron's Libtayo shows benefit in BCC By www.pharmatimes.com Published On :: Tue, 05 May 2020 11:01:09 +0100 BCC marks the second non-melanoma skin cancer for which Libtayo has demonstrated first-in-class data, the firms note Full Article
it US OK's AZ' Farxiga for heart failure with reduced ejection fraction By www.pharmatimes.com Published On :: Wed, 06 May 2020 12:13:58 +0100 Farxiga is the first sodium glucose co-transporter 2 inhibitor cleared by the FDA to treat heart failure with reduced ejection fraction Full Article
it US regulators permit AbbVie/Allergan merger By www.pharmatimes.com Published On :: Wed, 06 May 2020 12:23:42 +0100 The closing of the acquisition remains subject to other customary closing conditions Full Article
it Aberdeen Uni proceeds with COVID-19 mass screening research By www.pharmatimes.com Published On :: Wed, 06 May 2020 12:34:33 +0100 The Scottish government has given funds £101,903 to support the project Full Article
it Imperial College London partners with NHS Trust to make PPE By www.pharmatimes.com Published On :: Thu, 07 May 2020 07:39:19 +0100 More than 6,000 visors have already been delivered to Charing Cross Hospital Full Article
it E&C Members Hold Bipartisan Teleconference Forum with CDC on Racial Disparities in COVID-19 Health Outcomes By energycommerce.house.gov Published On :: Fri, 01 May 2020 00:00:00 -0400 Members of the Energy and Commerce Committee’s Health and Oversight and Investigations subcommittees today held a bipartisan teleconference forum with Centers for Disease Control and Prevention (CDC) Principal Deputy Director Anne Schuchat, M.D., to discuss racial disparities in health outcomes for COVID-19 patients. Health Subcommittee Chairwoman Anna G. Eshoo (D-CA), Health Subcommittee Ranking Member Michael C. Burgess, M.D. (R-TX), Oversight and Investigations Subcommittee Chair Diana DeGette (D-CO) and Oversight and Investigations Subcommittee Ranking Member Brett Guthrie (R-KY) released a joint statement following the call: “Today, bipartisan members of our two subcommittees discussed the deeply troubling racial disparities in health outcomes for COVID-19 patients with CDC’s Principal Deputy Director Schuchat. During the call, members received an update on CDC’s COVID-19 response, current data collection efforts, and reiterated the need for more accurate and timely demographic data. “Congress stands ready to work with the CDC to secure comprehensive demographic data to help us direct resources and support to close this gap in these health outcomes.” ### Full Article
it E&C Committee Members Hold Teleconference Forum with Admiral Giroir on COVID-19 Testing By energycommerce.house.gov Published On :: Mon, 04 May 2020 00:00:00 -0400 Energy and Commerce Committee members held a bipartisan teleconference forum with Admiral Brett P. Giroir, M.D., Assistant Secretary of Health at the Department of Health and Human Services, on the Administration’s COVID-19 testing efforts. Chairman Frank Pallone, Jr. (D-NJ) and Ranking Member Greg Walden (R-OR) released a joint statement following the call: “The Committee continued its discussions with federal health leaders today on the Administration’s ongoing response to the coronavirus pandemic. During the call, members received an update on federal efforts to increase COVID-19 testing and encouraged the Administration to continue working to get more testing supplies to communities in need. “The members asked for more specifics on the testing needs that states have identified, how the federal government is going to increase capacity and what level of testing is necessary to reopen the economy. “Testing is an essential tool in reducing the spread of this horrible virus, and we thank Admiral Giroir for providing the Committee an update today.” ### Full Article
it E&C Announces Hearing on Protecting Scientific Integrity in COVID-19 Response By energycommerce.house.gov Published On :: Thu, 07 May 2020 00:00:00 -0400 The Energy and Commerce Committee today announced a Health Subcommittee Hearing for Thursday, May 14, entitled “Protecting Scientific Integrity in the COVID-19 Response.” The hearing notice follows this note to the media. NOTE TO THE MEDIA: Due to COVID-19, the Committee will make every effort to adhere to the safety recommendations from the Centers for Disease Control and Prevention (CDC) and the Attending Physician. Therefore, media access will be limited. Please contact your respective gallery for details. As always, congressional press credentials will be required. May 7, 2020 HEARING NOTICE TO: Members of the Subcommittee on Health FROM: Anna G. Eshoo, Chairwoman SUBJECT: Subcommittee Hearing on “Protecting Scientific Integrity in the COVID-19 Response” The Subcommittee on Health of the Committee on Energy and Commerce will hold a hearing on Thursday, May 14, 2020, at 10 a.m. in the John D. Dingell Room, 2123 of the Rayburn House Office Building. The hearing is entitled, “Protecting Scientific Integrity in the COVID-19 Response.” Witnesses will be by invitation only. Among the witnesses invited to testify is Dr. Rick A. Bright, former Director of the Biomedical Advanced Research and Development Authority. The logistics of this hearing will be different due to the current circumstances of conducting a public hearing during the COVID-19 pandemic. Members will be advised regarding specifics on hearing procedures and briefings as soon as they become finalized. If you have any questions, please contact Meghan Mullon with the Committee staff at (202) 225-2927. The U.S. House of Representatives Office Buildings and the U.S. Capitol Complex are currently closed to the public. Official meetings of the Committee and its subcommittees are broadcast and available on the Committee’s website: www.energycommerce.house.gov. ### Full Article
it E&C Leaders Announce Committee Teleconference Forum on COVID-19 Testing, Contact Tracing and Surveillance on May 8 By energycommerce.house.gov Published On :: Thu, 07 May 2020 00:00:00 -0400 Energy and Commerce Chairman Frank Pallone, Jr. (D-NJ) and Ranking Member Greg Walden (R-OR) today announced that the Full Committee will hold a teleconference forum on Friday, May 8, at 12 pm (EDT) on COVID-19 testing, contact tracing and surveillance. “Our nation cannot effectively combat this terrible pandemic in the weeks and months ahead without significant testing, contact tracing and surveillance,” Pallone and Walden said. “We look forward to hearing from health experts about what actions they believe are necessary to ensure our communities have the resources they need to fight this pandemic and to confidently reopen their local economies.” During the forum, the Committee will hear from three health experts: Andy Slavitt, former Acting Administrator of the Centers for Medicare & Medicaid Services (CMS) from 2015-2017. Mark McClellan, M.D., Ph.D., former Administrator of CMS from 2004-2006 and former Commissioner of the Food and Drug Administration (FDA) from 2002-2004. Avik Roy,Co-founder and President of the Foundation for Research on Equal Opportunity. This forum is open to the press. Credentialed reporters interested in listening to the forum live should RSVP to cj.young@mail.house.gov by 4 pm today, Thursday, May 7. ### Full Article
it Consumer Protection and Commerce Subcommittee Announces Teleconference Forum with FTC Chairman Simons on May 11 By energycommerce.house.gov Published On :: Thu, 07 May 2020 16:35:29 -0400 Washington, D.C. – Consumer Protection and Commerce Subcommittee Chair Jan Schakowsky (D-IL) and Ranking Member Cathy McMorris Rodgers (R-WA) today announced that the Subcommittee will hold a teleconference forum on Monday, May 11, at 12 p.m. (EDT) with Federal Trade Commission (FTC) Chairman Joseph J. Simons to discuss critical consumer protection issues related to the COVID-19 pandemic. “The COVID-19 pandemic has brought about significant consumer protection concerns that fall under the purview of the FTC, including COVID-19 related scams, price gouging, privacy and data security issues, and more,” Schakowsky and McMorris Rodgers said. “We look forward to hearing from Chairman Simons about the steps FTC is taking to ensure consumers are protected during this pandemic.” This forum is open to the press. Credentialed reporters interested in listening to the forum live should RSVP to Evan.Gilbert@mail.house.gov by 5 pm on Friday, May 8. ### Full Article
it Hearing on Protecting Scientific Integrity in the COVID-19 Response By energycommerce.house.gov Published On :: Thu, 14 May 2020 10:00:00 -0400 The Subcommittee on Health of the Committee on Energy and Commerce will hold a hearing on Thursday, May 14, 2020, at 10 a.m. in the John D. Dingell Room, 2123 of the Rayburn House Office Building. The hearing is entitled, “Protecting Scientific Integrity in the COVID-19 Response.” Full Article
it Pfizer Pays Valneva $130M for a Bite at a Lyme Disease Vaccine By xconomy.com Published On :: Fri, 01 May 2020 22:44:06 +0000 If you’re looking for a Lyme disease vaccine, you can choose from among several—for your dog. A vaccine for humans hasn’t been available for years and few companies have tried to fill that void. Valneva has advanced its Lyme vaccine candidate to mid-stage clinical testing, and the company now has the help of drug giant […] Full Article Europe National blog main New York blog main New York top stories Biotech Centers for Disease Control and Prevention Cholera clinical trials deals Encephalitis FDA GlaxoSmithKline Japanese encephalitis Life Sciences Lyme disease LYMErix Pfizer pneumococcal disease Prevnar SmithKline Beecham Thomas Lingelbach Valneva
it Stemline Slated for Acquisition by Menarini in Deal Worth Up to $677M By xconomy.com Published On :: Mon, 04 May 2020 20:45:58 +0000 Stemline Therapeutics, whose drug for a rare, aggressive type of acute leukemia was approved by the FDA about 18 months ago, has signed an acquisition deal with Italian biopharma Menarini Group. Stemline (NASDAQ: STML), a New York-based company, developed the first FDA-approved drug for blastic plasmacytoid dendritic cell neoplasm, or BPDCN. The drug, tagraxofusp (Elzonris) […] Full Article Europe blog main National blog main New York New York blog main New York top stories Acquisition Biotech blastic plasmacytoid dendritic cell neoplasm Blood Cancer BPDCN clinical trials Deal Elcin Barker Ergun Ivan Bergstein Life Sciences M&A Menarini Merger Oncology Precision Medicine Stemline Therapeutics transaction
it Alexion Pharma Boosts Blood Drug Lineup With $1.4B Deal for Portola By xconomy.com Published On :: Tue, 05 May 2020 18:18:24 +0000 Alexion Pharmaceuticals has agreed to buy Portola Pharmaceuticals in a $1.4 billion deal that brings it a first-in-class therapy for treating life-threatening bleeding. According to financial terms announced Tuesday, Boston-based Alexion (NASDAQ: ALXN) will pay $18 for each outstanding share of Portola (NASDAQ: PTLA). That price is a a nearly 132 percent premium to Monday’s […] Full Article Boston Boston top stories Europe blog main National blog main National top stories San Francisco blog main San Francisco top stories Alexion Pharmaceuticals andexanet alfa Ardhana Sarin Betrixaban Biotech Bristol-myers Squibb clinical trials deals eculizumab FDA Geoffrey Porges Life Sciences Ludwig Hantson paroxysmal nocturnal hemoglobinuria Pfizer Portola Pharmaceuticals Ravulizumab SVB Leerink
it Ventus Launches With $60M to Shine Light on Innate Immune System Drugs By xconomy.com Published On :: Wed, 06 May 2020 17:07:49 +0000 The innate immune system has become a hot area for drug development, and for good reason. As the body’s first line of defense, its function (or dysfunction) plays a role in many diseases. The problem, says Ventus Therapeutics CEO Marcelo Bigal, is that drug developers have been working in the dark. Scientists don’t know the […] Full Article Boston Boston blog main Boston top stories National blog main San Diego blog main San Diego top stories San Francisco blog main San Francisco top stories Alphabet Biotech cancer cardiometabolic disorders deals Douglas Green Feng Shao gasdermin Genentech google GV Hao Wu Harvard Medical School IFM Therapeutics Immunology Inflammasome Inflammation Innate Immune System investing Jecure Therapeutics Judy Lieberman Labrys Biologics Life Sciences Marcelo Bigal National Institute of Biological Sciences nonalcoholic steatohepatitis Novartis Osteoarthritis Quench Bio Richard Flavell Roche Russell Vance St. Jude Children's Research Hospital startups Teva Pharmaceutical University of California at Berkeley Venture Capital Ventus Therapeutics Versant Ventures Yale University
it Novartis Drug Wins FDA Approval for Lung Cancers With Specific Mutation By xconomy.com Published On :: Thu, 07 May 2020 01:46:05 +0000 As cancer research reveals the genetic basis of the disease, pharmaceutical companies are pursuing targeted therapies that address certain groups of patients. One such drug from Novartis won FDA approval Wednesday, making it the first therapy cleared by the agency to treat patients whose non-small cell lung cancer (NSCLC) carries a certain genetic mutation. The […] Full Article National National blog main American Cancer Society Biotech cancer Cancer Drugs clinical trials companion diagnostic FDA Foundation Medicine Incyte kinase inhibitor Life Sciences myelofibrosis Novartis ruxolitinib
it Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health By xconomy.com Published On :: Thu, 07 May 2020 13:15:48 +0000 Learn how digital tech is accelerating medical breakthroughs by registering your team to attend Xcelerating Life Sciences Boston: Biopharma’s Future in Digital Health. While some content focuses on the Boston ecosystem, we’re confident the forum – and virtual networking – will be valuable to a national audience. The May 13, 2020 event will explore the […] Full Article Boston Boston blog main Boston top stories National National blog main National top stories Biotech event Life Science Life Sciences
it Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More By xconomy.com Published On :: Fri, 08 May 2020 14:33:23 +0000 Alexion Pharmaceuticals CEO Ludwig Hantson has made no secret that he wants to diversify his company’s drug portfolio and he has shown willingness to open the corporate checkbook to accomplish that goal. Last October, Alexion (NASDAQ: ALXN) struck a $930 million deal to acquire Achillion Pharmaceuticals, a biotech whose lead drug complements the Boston company’s […] Full Article Boston blog main Boston top stories Boulder/Denver blog main Boulder/Denver top stories Detroit blog main Detroit top stories Europe blog main Europe top stories Indiana blog main Indiana top stories National National blog main National top stories New York blog main New York top stories Raleigh-Durham blog main Raleigh-Durham top stories San Diego blog main San Diego top stories San Francisco blog main San Francisco top stories Seattle blog main Seattle top stories Texas blog main Texas top stories Wisconsin blog main Wisconsin top stories AbbVie Achillion Pharmaceuticals Akcea Therapeutics Alexion Pharmaceuticals Alnylam Pharmaceuticals andexanet alfa Antibe Therapeutics Apotex Arrowhead Pharmaceuticals AstraZeneca Avrobio Axcella Health. Newron Pharmaceuticals basal cell carcinoma BioMarin Pharmaceutical BioNtech Biotech blastic plasmacytoid dendritic cell neoplasm Bristol-myers Squibb Bruce Given cancer Cardiff Oncology Carla Poulson Celgene Cell Therapy cemiplimab Censa Pharmaceuticals Chemotherapy chlorambucil Chronic Lymphocytic Leukemia Clarametyx Biosciences Clostridium difficile COVID-19 CRISPR dapagliflozin Diagnostics DiNAQOR dry eye disease epilepsy Federal Trade Commission Ferring Pharmaceuticals FogPharma Fragile X Syndrome Gemini Therapeutics Gene Therapy Gilead Sciences Grail Incyte Innate Immune System investing Joseph Stauffer Kala Pharmaceuticals Kezar Life Sciences Kura Oncology Life Sciences lisocaptagene maraleucel Ludwig Hantson Magenta Therapeutics Marc Uknis Mark Erlander Menarini Group Microbiome microbiome drugs Myonexus Therapeutics Neurological Diseases Noreen Roth Henig Novartis Obinutuzumab Ovid Therapeutics Pfizer Portola Pharmaceuticals pravastatin Praxis Precision Medicines PTC Therapeutics rare disease drugs rebiotix Regeneron Pharmaceuticals remdesirvir Rett syndrome Sanofi Sarepta Therapeutics sarizotan Sherlock Biosciences startups Stemline Therapeutics systolic heart failure TG Therapeutics Tony Gibney TrovaGene U.S. Department of Justice ublituximab umbralisib Ventus Therapeutics Vir Biotechnology
it Eli Lilly Gets Edge in the “RET” Race With FDA Nod for Cancer Drug By xconomy.com Published On :: Sat, 09 May 2020 02:33:40 +0000 Eil Lilly received accelerated FDA approval Friday for a drug that treats advanced cancers carrying a certain genetic signature. It’s the latest targeted cancer therapy to pass the regulatory bar and the first that addresses tumors characterized by aberrations in one particular gene. The gene in question, RET, produces a protein involved in cell signaling. […] Full Article Boston blog main Boston top stories Indiana Indiana blog main Indiana top stories National blog main National top stories New York blog main New York top stories Biotech Blueprint Medicines cancer Cancer Drugs clinical trials Eli Lilly FDA Life Sciences medullary thyroid cancer Non-Small Cell Lung Cancer Novartis pralsetinib selpercatinib Thyroid Cancer
it Dr John McHutchinson steps down from Gilead with $1.1 million goodbye By www.pharmafile.com Published On :: Thu, 18 Jul 2019 16:03:27 +0000 Gilead has said that Dr John McHutchison is stepping down after nine years at the firm. Gilead’s Chief Scientific Officer and Head of Research and Development has decided to leave the company next month, Gilead said. Under McHutchinson, Gilead developed five new hepatitis drugs, which have been used by as many as 3.2 million people around the world. read more Full Article Research and Development Medical Communications Sales and Marketing Business Services Manufacturing and Production
it Christi Shaw taken on by Gilead as Kite Pharma's new CEO By www.pharmafile.com Published On :: Thu, 25 Jul 2019 14:43:03 +0000 Lilly veteran Christi Shaw has joined Kite Pharma as the company’s new CEO. Shaw comes to Gilead’s cancer immunotherapy firm, Kite Pharma, from rival US firm Eli Lilly, where she acted as a senior vice president and also as president of Lilly’s immunology, pain and neuroscience unit, Lilly Bio Medicines. read more Full Article Research and Development Medical Communications Sales and Marketing Business Services Manufacturing and Production
it Dr Wajid Hussain appointed new clinical director for digital health at RCP By www.pharmafile.com Published On :: Fri, 02 Aug 2019 11:20:05 +0000 The Royal College of Physicians (RCP) has appointed Dr Wajid Hussain as its new clinical director for digital health. Dr Hussain, a cardiologist and cardiac electrophysicist at the Royal Brompton and Harefield NHS Trust, has a demonstrated interest in IT and health. While he currently represents the views of clinicians on the Trust’s IT committee, Dr Hussain completed a Diploma in Digital Health Leadership at the NHS Digital Academy last year. He is also currently studying for a Master’s in Digital Health leadership at Imperial College London. read more Full Article digital health IT pharma RCP Research and Development Royal College of Physicians Medical Communications Sales and Marketing Business Services Manufacturing and Production
it Chris Whitty begins role as England’s Chief Medical Officer By www.pharmafile.com Published On :: Tue, 01 Oct 2019 10:12:19 +0000 London consultant and public health professor, Chris Whitty, has begun his role as England’s Chief Medical Officer, taking over from Dame Sally Davies, who has now stepped down from the position. Whitty has served as the Department of Health and Social Care’s Chief Scientific Adviser since 2016 and was announced as Dame Sally Davies successor earlier in June this year. read more Full Article Research and Development Medical Communications Sales and Marketing Business Services Manufacturing and Production
it Alligator Bioscience hires Chief Financial Officer in interim capacity By www.pharmafile.com Published On :: Mon, 09 Mar 2020 17:21:44 +0000 Andreas Johannesson has been announced as Alligator Bioscience’s new interim Chief Financial Officer (CFO), replacing ex-CFO Per-Olof Schrewelius who it was previously confirmed will no longer serve the company. Johannesson’s career has spanned 15 years in the consumer goods sector, with him managing the finances of firms including TeamOlmed, Stenqvist, Fitness23Seven and Haldex. He spent a further nine years of his career as a strategic consultant with a focus on consumer goods, five of which were spent at global consulting firm McKinsey & Company. read more Full Article Alligator Bioscience pharma Research and Development Medical Communications Sales and Marketing Business Services Manufacturing and Production
it Dr Maritza McIntyre appointed Chief Development Officer at StrideBio By www.pharmafile.com Published On :: Wed, 08 Apr 2020 16:36:52 +0000 StrideBio have announced the appointment of Maritza McIntyre Ph.D., as its first Chief Development Officer. The newly created role will see Dr McIntyre oversea the translational development of the company’s research-stage gene therapy programs. This includes regulatory filings, initiating early clinical studies and starting Investigational New Drug enabling preclinical studies. read more Full Article Research and Development Medical Communications Sales and Marketing Business Services Manufacturing and Production
it Lawsuits as Conduits for Misinformation During COVID-19 By blog.petrieflom.law.harvard.edu Published On :: Thu, 30 Apr 2020 12:00:51 +0000 In addition to tracing the early history of the Missouri and New York suits, we explain how these lawsuits are being used as conduits for misinformation. The post Lawsuits as Conduits for Misinformation During COVID-19 appeared first on Bill of Health. Full Article Featured Health Law Policy International Liability China coronavirus coronavirus pandemic COVID-19 COVID19 eric schmitt foreign sovereignty immunities act fsia Health Law Missouri new york world health organization
it COVID-19 is a Perfect Storm of Hardship for US Immigrant Communities By blog.petrieflom.law.harvard.edu Published On :: Mon, 04 May 2020 12:00:05 +0000 Immigrant communities, along with communities of color and people experiencing existing health inequities, are expected to face disproportionate effects. The post COVID-19 is a Perfect Storm of Hardship for US Immigrant Communities appeared first on Bill of Health. Full Article Featured Health Law Policy Immigration Patient Care Public Health Race Social Determinants of Health coronavirus coronavirus pandemic COVID-19 COVID19 health disparities immigrants immigration and customs enforcement immigration status
it Obtaining a Hospital Bed in the COVID-19 Pandemic: A Legal Perspective By blog.petrieflom.law.harvard.edu Published On :: Tue, 05 May 2020 12:00:10 +0000 A judge ruled recently that a patient, known as MB, who had occupied an NHS bed for over a year, must vacate it and instead receive care in the community. The post Obtaining a Hospital Bed in the COVID-19 Pandemic: A Legal Perspective appeared first on Bill of Health. Full Article Health Law Policy John Tingle Patient Care Public Health Resource Allocation Community Care COVID-19 Global Health global patient safety Health Law health law policy housing Mental Health Public Health Law Research
it How States are Protecting Health Care Providers from Legal Liability in the COVID-19 Pandemic By blog.petrieflom.law.harvard.edu Published On :: Tue, 05 May 2020 17:30:58 +0000 Clinicians and policymakers alike are raising the alarm about potential legal liability for following crisis standards of care during the COVID-19 pandemic. The post How States are Protecting Health Care Providers from Legal Liability in the COVID-19 Pandemic appeared first on Bill of Health. Full Article Health Law Policy Liability Patient Care Professional Regulation coronavirus coronavirus pandemic COVID-19 COVID19 crisis standards of care Health Law legal liability Malpractice Medical Malpractice valerie gutmann koch
it Access to Drugs Before FDA Approval: Video Explainer with Christopher Robertson By blog.petrieflom.law.harvard.edu Published On :: Thu, 07 May 2020 14:55:20 +0000 In this video explainer, Christopher Robertson discusses the Right to Try Act and off-label use of pharmaceuticals with Alison Bateman-House. The post Access to Drugs Before FDA Approval: Video Explainer with Christopher Robertson appeared first on Bill of Health. Full Article Christopher Robertson FDA Health Law Policy Off-Label Use Pharmaceuticals Public Health alison bateman-house christopher robertson coronavirus coronavirus pandemic COVID-19 COVID19 off-label use Regulation right to try
it Hospital Administration and the COVID-19 Pandemic (Part II) By blog.petrieflom.law.harvard.edu Published On :: Fri, 08 May 2020 15:27:58 +0000 A discussion of administrative decisions hospitals are making during the COVID-19 pandemic, including cutting benefits for employees and furloughing staff. The post Hospital Administration and the COVID-19 Pandemic (Part II) appeared first on Bill of Health. Full Article Chloe Reichel Contributors Health Care Finance Health Law Policy Patient Care Petrie-Flom Center Public Health coronavirus pandemic COVID-19 COVID19 for-profit hospitals hospital administration Hospitals not-for-profit hospitals rina spence
it Pharma Billionaire Charged With Penny Stock Fraud By www.forbes.com Published On :: Fri, 07 Sep 2018 20:22:00 +0000 Miami’s Phillip Frost, who built a $2.8 billion fortune in the generic drug business, was allegedly involved in a tawdry stock promotion scheme, the Securities and Exchange Commission says. Full Article ticker=NYSE:OPK byline=Matthew Herper